Country
Clinical Trials in Argentina
Studies with at least one site in Argentina. Open a trial for its sites in Argentina, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 643Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- Trial name
- MagnetisMM-6 (NCT05623020)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 1,060 people
- Sponsor
- Pfizer
Fibrosing Interstitial Lung Disease
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary…
- Trial name
- NCT07366034
- Testing
- Nerandomilast
- Where
- 47 sites in United States, Argentina and 20 more
- Volunteers
- 35 people
- Sponsor
- Boehringer Ingelheim
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- emnergize (NCT07091630)
- Testing
- Empasiprubart IV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 160 people
- Sponsor
- argenx
Polyneuropathy, Inflammatory Demyelinating, Chronic
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating…
- Trial name
- LTS (NCT06859099)
- Testing
- Riliprubart Prefilled Pen (PFP)
- Where
- 63 sites in United States, Argentina and 22 more
- Volunteers
- 300 people
- Sponsor
- Sanofi
Ulcerative Colitis, Inflammatory Bowel Diseases
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
- Trial name
- SKYLINE-UC (NCT07012395)
- Testing
- SPY001, SPY002, SPY003
- Where
- 276 sites in United States, Argentina and 33 more
- Volunteers
- 645 people
- Sponsor
- Spyre Therapeutics, Inc.
Niemann-Pick Type C Disease, GM1 Gangliosidosis
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in…
- Conditions
- Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
- Trial name
- NCT07054515
- Testing
- AZ-3102
- Where
- 39 sites in United States, Argentina and 15 more
- Volunteers
- 147 people
- Sponsor
- Azafaros B.V.
Non-small Cell Lung Cancer, NSCLC
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line…
- Trial name
- NCT06422143
- Testing
- Pembrolizumab, sac-TMT, Carboplatin
- Where
- 217 sites in United States, Argentina and 24 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with…
- Trial name
- NCT06875310
- Testing
- Adagrasib, Pembrolizumab, Carboplatin
- Where
- 317 sites in United States, Argentina and 33 more
- Volunteers
- 630 people
- Sponsor
- Mirati Therapeutics Inc.
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS).
- Trial name
- TroFuse-007 (NCT06170788)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
- Where
- 220 sites in United States, Argentina and 24 more
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD).
- Trial name
- FIORELLO (NCT07192952)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 132 sites in United States, Argentina and 21 more
- Volunteers
- 117 people
- Sponsor
- Bayer
Completed, with results posted
All 1,729Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer
- Trial name
- RECITE (NCT03362177)
- Testing
- Romiplostim
- Where
- 117 sites in United States, Argentina and 18 more
- Volunteers
- 165 people
- Sponsor
- Amgen
Substance Abuse, HIV
Electronic SBI(RT) for MSM in Argentina
The main goal of this pilot randomized controlled trial (RCT) with 200 participants is to establish the processes and procedures for a subsequent large-scale efficacy trial of an electronic-Screening, Brief Intervention, Referral…
- Trial name
- NCT05542914
- Testing
- electronic screening and brief intervention., Phase 2: Assessment Only
- Where
- Argentina
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Florida State University
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or…
- Trial name
- NCT05037929
- Testing
- Astegolimab
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 1,334 people
- Sponsor
- Genentech, Inc.
Acute Myeloid Leukemia (AML)
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia…
- Trial name
- NCT03069352
- Testing
- Venetoclax, Cytarabine
- Where
- 109 sites in United States, Argentina and 22 more
- Volunteers
- 211 people
- Sponsor
- AbbVie
Metastatic Breast Cancer
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2…
- Trial name
- Next MONARCH 1 (NCT02747004)
- Testing
- Abemaciclib, Tamoxifen, Prophylactic Loperamide
- Where
- 59 sites in United States, Argentina and 12 more
- Volunteers
- 234 people
- Sponsor
- Eli Lilly and Company